Recordati (OTCMKTS:RCDTF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.
According to Zacks, “Recordati S.p.A. is a pharmaceutical company. It engaged in the research, development, manufacturing and marketing of pharmaceuticals for rare disease treatments. The company operates primarily in Russia, Turkey, North Africa and United States of America. Recordati S.p.A. is headquartered in Milan, Italy. “
RCDTF stock opened at $34.70 on Thursday. The company has a market capitalization of $7.26 billion, a P/E ratio of 21.96, a P/E/G ratio of 2.50 and a beta of 0.06. Recordati has a 52 week low of $34.70 and a 52 week high of $34.87.
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals in Europe, the Middle East, Africa, the United States, Canada, and internationally. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, cosmetics, dermatology, dietary supplements, gynecology and obstetrics, medical devices, musculo-skeletal disorders and analgesia, over the counter/non-prescription pharmaceuticals, urology, allergy, anti-infectives, central nervous system, endocrinology, gastrointestinal, nutrition and related products, immune-suppressants, pain management/inflammation, generics, pneumology, antipyretics and cold preparations, endocrinology, oncology, respiratory, and radio contrast agent, as well as ear, nose, and throat.
Featured Story: Bear Market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recordati Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati and related companies with MarketBeat.com's FREE daily email newsletter.